Connect with us

Cannabis News

Connecticut Governor Signs Bill To Expand Psychedelics Pilot Program In Preparation For Federal FDA Approval

Published

on

Connecticut’s governor has signed a bill to expand a pilot program explore the therapeutic potential of psychedelics such as psilocybin and MDMA.

The legislation, sponsored by the Joint Committee on Public Health, cleared the House of Representatives on a 122-27 vote last month, after passing the Senate by a unanimous 35-0 vote in April.

Gov. Ned Lamont (D) signed it into law Thursday.

The new law builds on it an existing psychedelic-assisted therapy program involving military veterans and first responders who choose to participate in clinical trials.

It also repeals and replaces existing statute, adults 18 or older who meet clinical eligibility criteria established by the medical school institutional review board selected to administer the pilot program. may be eligible for psychedelic treatment in a clinical settingwith researchers responsible for studying the effectiveness of novel therapeutics.

It also removes existing language specifying that the pilot program must end upon approval of federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency.

Finally, he calls the state Department of Mental Health and Addiction Services to create and facilitate the program by January 2023.

Rep. Cristin McCarthy Vahey (D) said before the House vote that the legislation is “critically important,” citing recent moves by federal officials. accelerate research and therapeutic access to psychedelics after President Donald Trump signed an executive order on the matter in April

“If fast track is successful and these drugs are approved, our study will be terminated, and as a result, we will not be able to continue the study and lose the benefit of the investment we have already made as a state, but will also make us ineligible for those federal matching funds,” he said on the floor.

According to the Connecticut bill, SB 191officials to “establish, within available appropriations, a pilot psychedelic-assisted therapy program to be administered by a state medical school.” That program will “provide MDMA or psilocybin-assisted therapy to qualified patients as part of a research program approved by the Federal Food and Drug Administration,” or FDA, it says.

Rep. Nicole Klarides-Ditria (R) also spoke in support of the legislation, saying “this expanded access is groundbreaking research. It’s evidence-based research. Mental health and treatment are critical to the state of Connecticut.”

“Extending it to anyone over the age of 18 will really help us continue this pilot program,” he said.

To that point, McCarthy Vahey said that due to the constraints of the current structure there have been difficulties in recruiting enough participants.

“The current pilot is very focused and tailored. And in fact, the priority will be to make veterans, first responders and our direct health care workers the focus of the research,” he said. “But they tell us they’re having a little difficulty recruiting some people. The goal is to get to a cohort of 50, so this will give them a little bit of a chance to do that.”

Rep. Dave Yaccarino (R) said he voted against the original psychedelic program legislation a few years ago, but has since heard of studies showing benefits “for the men and women who come out of combat, our firefighters, our police officers who witness tragic events.”

“If this helps, and it’s controlled, I think you should accept it,” he said.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Meanwhile, last year The Connecticut House of Representatives passed a bill to decriminalize psilocybin for adults—Despite being asked if the governor would accept it after rejecting a previous version of the reform measure.

This was the third consecutive session in which Connecticut lawmakers worked to decriminalize psilocybin. in 2023, the reform measure cleared the House but it did not move from the Senate. The The Judiciary Committee also approved a version in 2024.

Lamont also signed a major budget bill in 2022 that included provisions for statehood. providing some patients with access to psychedelic-assisted treatment Using substances like MDMA and psilocybin.

Lawmakers also sent the governor’s legislation this session address the THC potency limit of the cannabis product.

Separately, legislation allow the use of medical marijuana in health care facilities by some eligible patients such as hospitals, nursing homes and hospices received a committee hearing but did not move forward.

user photo Mark Groeneveld.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Redefining the standards of UK cannabis

Published

on

By

Dalgety Ltd has entered into a partnership with Curaleaf Laboratories to supply pharmaceutical grade cannabis medicines to the UK cannabis market. The arrangement combines Dalgety’s cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply route that does not rely on imported cannabis flowers, as Dalgety cultivates its product in-house. Dalgety claims it was the first company in the UK to grow, manufacture and supply EU-GMP medical cannabis from a single site.

© Curaleaf Laboratories

The growing facility, which is more than 30,000 square feet, is located indoors and uses hydroponic growing methods along with automated lighting, irrigation, humidity and temperature control systems. The company reports that it uses AI-assisted environmental monitoring, which extends the traceability of batches to the final product and compares them to operating standards for air filtration systems. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.

The stated goal of this approach is to reduce between-harvest variation in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says his cultivation is overseen by staff with experience in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.

Through a partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis is processed and distributed through a UK-based supply chain, rather than imported from overseas. Companies suggest that this arrangement can shorten the time it takes to get products to market compared to importing, and reduce the likelihood of supply disruptions. Because Dalgety and Curaleaf Laboratories are involved in cultivation, manufacturing and distribution, the companies say this oversees the product at every stage, making it clearer for prescribers to see where and how the product was made.

© Curaleaf Laboratories

Dalgety operates to EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures and quality assurance processes, along with controlled and secure facilities.

The company describes its work as controlled environment farming, hydroponic systems, environmental control technology, and efforts to stabilize cannabis genetics and phenotypes for batch-to-batch consistency.

© Curaleaf Laboratories

Dalgety has also opened its cultivation facilities for visits to healthcare professionals, clinicians, pharmacists, researchers and other industry stakeholders. The company says this is in response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which has limited opportunities for UK clinicians to see first-hand the cultivation and quality control processes. These tours aim to provide visitors with information on cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes and the regulatory framework governing cannabis manufacturing in the UK.

Dalgety and Curaleaf Laboratories describe their partnership as expanding access to UK-grown medical cannabis, improving supply chain reliability and helping to meet sector regulations, placing it in the wider context of growing demand for cannabis-based treatments from UK patients.

For more information:
Curaleaf Laboratories
Email: (email protected)
https://curaleaflaboratories.co.uk/

Continue Reading

Cannabis News

Arkansas GOP Governor And Democratic Challenger Agree On Opposing Marijuana Legalization

Published

on

By

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans.”

Antoinette Grajeda, Arkansas attorney

Contains medical marijuana It generated more than $1 billion since Arkansas voters legalized it in 2016

After the state opened its first dispensary in 2019, thousands of Arkansans joined the program and spent a record $291.1 million on medical marijuana in 2025, according to the state Department of Finance and Administration.

Tax revenue from those sales now supports free breakfast for public school students after lawmakers passed legislation last year.

Medical marijuana programs have expanded across the country, as has recreational marijuana. Two dozen states, including neighboring Missouri, allow recreational marijuana use, according to state legislatures.

Arkansas voters rejected an effort to legalize recreational marijuana in 2022despite the national teams spending millions in support of the measure.

Restrictions on marijuana have been relaxed at the federal level, and the US Department of Justice earlier this year downgraded the drug classification of medicinal cannabis.

Here’s what Arkansas’ gubernatorial candidates — Democratic State Sen. Fred Love, Republican Gov. Sarah Huckabee Sanders and Libertarian Colt Shelby — have to say about legalizing recreational marijuana.

Democratic State Sen. Fred Love

Love said he opposes legalization during a debate at the Arkansas Press Association’s annual conference in June.

Sitting in a crosswalk at her daughter’s school, Love said “marijuana is all over” as the children exited their vehicles. When you grow up in a community where recreational marijuana is present, you see that it doesn’t always have a positive effect, he said.

“I don’t think it’s something I support,” Love said. “I’ve seen the long-term impact.”

While he doesn’t personally support it, Love said he would support legalizing recreational marijuana if Arkansans voted on it.

Libertarian Colt Shelby

Shelby said he’s for whatever Arkansans want, so he would support legalizing recreational marijuana if voters approve.

Shelby said the state’s elected officials have forgotten what matters most is what Arkansans want, which is why she’s running for office.

Although Shelby says she doesn’t smoke weed herself, she says almost everyone knows it and she has the meds.

“It brings a lot of good things, so I won’t say that I’m against it, but let the people decide”, he said in the debate in June.

Republican Governor Sarah Huckabee Sanders

Sanders did not participate in the June debate, but said in an emailed statement that he does not support the legalization of recreational marijuana.

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans,” Sanders said.

Sanders vetoed a law passed by the Legislature last year dispensaries have been allowed to deliver orders via a delivery vehicle or drive-through window.

The governor signed into law in 2023 the bill protecting the rights for medical marijuana patients and caregivers to obtain a license to carry a concealed handgun.

In 2025, Sanders backed that uses medical marijuana revenue to support free breakfast for all public school students.

This story was first published by the Arkansas Advocate.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Will the top World Cup expert in the fruit, vegetable, and horticulture sector come from Canada, the U.S. or Belgium?

Published

on

By






FreshPublishers 2026 World Cup Group Stage






The World Cup is coming to an end, with the third-place play-off between France and England on Saturday, and the final between Spain and Argentina the following day. It won’t be long until the grand winner of FreshPublishers’ first World Cup pool is revealed.

© Fresh Publishers

As previously reported, Slim Kooli from Courchesne Laros is the favorite to win the €1,000 prize. He has secured a comfortable lead over Nol Batist of North American Interstate Greenhouse Company, while buyer Bjorn Van Ryckeghem of Deprez Construct is currently in third place.

1 Sim School Spain 1–0 2–1 737 9716
2 Nol Batist France 2–1 1–1 674 9433
3 Bjorn Van Ryckeghem France 2–2 3–1 674 9264
4 Christian Anton Smedshaug England 1–2 1–2 659 9134
5 Perry Springintveld Spain 1–1 2–1 647 9105
6 Willem Tijssen Spain 2–0 2–1 710 9098
7 Hans Borsboom Spain 2–1 2–1 528 9058
8 Bart Triemstra Spain 2–1 2–1 737 9052
9 Youness Bensaid Spain 2–1 1–1 722 8954
10 Vijay Dijkstra Portugal 2–0 2–1 382 8953

However, there have been some surprises during the tournament, and bonus points must be added, so we will keep the suspense a little longer. On Monday we will find out who is the main World Cup announcer in the international fruit, vegetable and horticulture sector…



Publication date:













Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media